Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a ...

SAN DIEGO, May 15, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by ...

Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

On Monday, Leerink Partners made an adjustment to the price target of Janux Therapeutics (NASDAQ: JANX) shares, lowering it slightly from $91.00 to $89.00, while maintaining an Outperform rating ...

SAN DIEGO, May 15, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying ...

In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other oversold biotech stocks to buy now. Biotechnology stocks are among the most ...

In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Therapeutics to bring T-cell immunotherapies to cancer patients. The agreement sees San Diego-based Janux in ...

In a challenging market environment, Janux Therapeutics, Inc. (JANX) stock has touched a 52-week low, dipping to $33.29. According ...

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Janux Therapeutics, Inc. (JANX) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home page ...